← Leaderboards
Judith Tsui
Boston Medical Center
$9,934,962
Attributed
$16,334,420
Total exposure
14
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,334,420 · 14
By mechanism
R44$4,728,792 · 2
U24$3,717,717 · 1
R25$2,249,652 · 1
R34$1,485,590 · 2
UH3$1,035,733 · 1
T32$956,054 · 1
Top collaborators
- Sebastian Seiguer9 shared
- Heidi M. Crane5 shared
- Jeffrey H Samet5 shared
- Geetanjali Chander3 shared
- Kevin A. Hallgren3 shared
- Emily Caterina Williams3 shared
- Sara Nelson Glick1 shared
Most similar at Boston Medical Center
Same institution · by research overlap
- C Robert Horsburgh$21,596,833
- Sabrina A Assoumou$4,255,025
- Rachel Lee Epstein$769,863
- Joshua Adam Barocas$5,317,959
- Jane M Liebschutz$5,811,997
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCaringAddictionOpioid Use DisorderFundingOpioid EpidemicInnovationPersonsOpioidLeadPreventEpidemicMedicalFutureProgramsHepatitis CTrainingResearch PersonnelAffectHiv/HcvSubstance Use DisorderUnited StatesOverdoseOpioid Use
Grant awards (41)
A Hybrid Implementation-Effectiveness Study of the Pharmacist, Physician, and Patient Navigator Collaborative Care Model to cure Hepatitis C among persons who use drugs with housing insecurity$777,497
R01 · FY2025 · DA · contact PI
Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program$650,426
R44 · FY2025 · DA
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States$374,800
R25 · FY2025 · DA · contact PI
Training in Enhancing Structural Solutions in Addictions (TESSA) Programâ$355,747
T32 · FY2025 · DA
SWG 11: Substance Use$39,491
P30 · FY2025 · AI · contact PI
Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program$659,386
R44 · FY2024 · DA
Training in Equity and Structural Solutions in Addictions (TESSA)$406,734
T32 · FY2024 · DA
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States$376,936
R25 · FY2024 · DA · contact PI
SWG 11: Substance Use$34,602
P30 · FY2024 · AI · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$733,846
U24 · FY2023 · DA
Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program$654,494
R44 · FY2023 · DA
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States$376,936
R25 · FY2023 · DA · contact PI
Training in Equity and Structural Solutions in Addictions (TESSA)$193,573
T32 · FY2023 · DA
Patient Navigator plus Remote mHealth Adherence Support with Incentives: Understanding Criminal Justice Effects$142,070
R34 · FY2023 · DA · contact PI
SWG 11: Substance Use$48,723
P30 · FY2023 · AI · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$739,908
U24 · FY2022 · DA
Patient Navigator plus Remote mHealth Adherence Support with Incentives to Improve Linkage and Retention among Hospitalized Patients with Opioid and Methamphetamine Use Who Initiate Buprenorphine$699,750
R34 · FY2022 · DA · contact PI
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States$376,936
R25 · FY2022 · DA · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$754,049
U24 · FY2021 · DA
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States$376,936
R25 · FY2021 · DA · contact PI
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol Problems$357,152
UH3 · FY2021 · AA
Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs$214,590
R34 · FY2021 · DA · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$754,049
U24 · FY2020 · DA
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States$367,108
R25 · FY2020 · DA · contact PI
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol Problems$354,565
UH3 · FY2020 · AA
Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program$224,940
R41 · FY2020 · DA
Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs$214,590
R34 · FY2020 · DA · contact PI
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$828,035
R44 · FY2019 · DA
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$735,865
U24 · FY2019 · DA
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$623,635
R44 · FY2019 · DA
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$355,967
R44 · FY2019 · DA
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol Problems$324,016
UH3 · FY2019 · AA
Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs$214,590
R34 · FY2019 · DA · contact PI
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$731,871
R44 · FY2018 · DA
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol Problems$169,234
UH2 · FY2018 · AA
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$224,978
R44 · FY2017 · DA
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol Problems$215,495
UH2 · FY2017 · AA
HCV and Pain in Substance Users With and Without HIV$161,973
K23 · FY2013 · DA · contact PI
HCV and Pain in Substance Users With and Without HIV$167,211
K23 · FY2012 · DA · contact PI
HCV and Pain in Substance Users With and Without HIV$171,369
K23 · FY2011 · DA · contact PI
HCV and Pain in Substance Users With and Without HIV$150,347
K23 · FY2010 · DA · contact PI